Laboratorio de Inmunología y Patogénesis Parasitarias (LIPAP)

Directora:

Dra. Alba Soto, Catalina Dirney

Integrantes:

Dra. Solana, María Elisa

Marchetto, Matias Ildebrando

Med. Colaiani, Ivana

Apaza Zela, Herbert Jesús

Colaboradores:

Alan Talevi, PhD, Laboratorio de Investigación y Desarrollo de Bioactivos.  Facultad de Ciencias Exactas, Universidad Nacional de La Plata.(https://lideb.biol.unlp.edu.ar/)

Silvia Repetto, MD. PhD. Laboratorio de Parasitología Clínica y Molecular (LPCM) (https://impam.conicet.gov.ar/lpcm/)

Lucia Gallo Vaulet, PhD. Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Buenos Aires, Argentina. Facultad de Farmacia y Bioquímica. Universidad de Buenos Aires. (https://infibioc.com.ar/grupo_investigacion/microbiologia-clinica-inmunologia-y-virologia-clinica/)

Eduardo Maldonado, DVM. PhD. Medical University of South Carolina. Drug Discovery & Biomedical Sciences (https://medicine.musc.edu/departments/dom/divisions/gastroenterology/research/labs-and-centers/ddrcc/member-)

Guillermo Alonso, PhD. Grupo de Señalización y Mecanismos Adaptativos en Tripanosomátidos. INGEBI – CONICET Instituto de Investigaciones en Ingeniería Genética y Biología Molecular “Dr. Héctor N. Torres” (http://ingebi-conicet.gov.ar/es_senalizacion-y-mecanismos-adaptativos-en-tripanosomatidos/)

Nuestras líneas de trabajo abarcan diversos aspectos de la respuesta inmune, patogenia y tratamiento de enfermedades desatendidas con especial énfasis en la Enfermedad de Chagas. Nos interesa el trabajo de investigación con un enfoque de traslacional de lo básico a lo clínico para lo cual colaboramos con farmacólogos y profesionales clínicos de diversas especialidades.

- Búsqueda de biomarcadores inmunológicos predictores de la evolución de la enfermedad de Chagas.

- Estimación del riesgo de reactivación de T. cruzi en pacientes bajo tratamiento inmunosupresor.

- Desarrollo de modelos experimentales preclínicos que permitan estudiar la reactivación de T. cruzi.

- Diseño de estrategias farmacológicas para el control de la enfermedad de Chagas crónica.

Publicaciones destacadas:

- Muraca G, Ruiz ME, Gambaro RC, Scioli-Montoto S, Sbaraglini ML, Padula G, Cisneros JS, Chain CY, Álvarez VA, Huck-Iriart C, Castro GR, Piñero MB, Marchetto MI, Alba Soto C, Islan GA, Talevi A. Nanostructured lipid carriers containing benznidazole: physicochemical, biopharmaceutical and cellular in vitro studies. Beilstein J Nanotechnol. 2023 Jul 28;14:804-818. eCollection 2023. https://doi: 10.3762/bjnano.14.66

- Llanos MA, Alberca LN, Ruiz MD, Sbaraglini ML, Miranda C, Pino-Martinez A, Fraccaroli L, Carrillo C, Alba Soto CD, Gavernet L, Talevi A. A combined ligand and target-based virtual screening strategy to repurpose drugs as putrescine uptake inhibitors with trypanocidal activity. J Comput Aided Mol Des. 2023 Feb;37(2):75-90. doi: 10.1007/s10822-022-00491-0

- Grijalva A, Gallo Vaulet L, Agüero RN, Toledano A, Risso MG, Quarroz Braghini J, Sosa D, Ruybal P, Repetto S, Alba Soto CD. Interleukin 10 Polymorphisms as Risk Factors for Progression to Chagas Disease Cardiomyopathy: A Case-Control Study and Meta-Analysis. Front Immunol. 2022 Jul 4;13:946350. doi: 10.3389/fimmu.2022.946350.

- Rodríguez-Durán J, Gallardo JP, Alba Soto CD, Gómez KA, Potenza M. The Kinetoplastid-Specific Protein TcCAL1 Plays Different Roles During In Vitro Differentiation and Host-Cell Invasion in Trypanosoma cruzi. Front Cell Infect Microbiol. 2022 Jun 30;12:901880. doi: 10.3389/fcimb.2022.901880

- Pineda GE, Rearte B, Todero MF, Bruballa AC, Bernal AM, Fernandez-Brando RJ, Isturiz MA, Zotta E, Alba-Soto CD, Palermo MS, Ramos MV. Absence of interleukin-10 reduces progression of shiga toxin-induced hemolytic uremic syndrome. Clin Sci (Lond). 2021 Feb 12;135(3):575-588. doi:10.1042/CS20200468

- Rada J, Donato M, Penas FN, Alba Soto C, Cevey ÁC, Pieralisi AV, Gelpi R, Mirkin GA, Goren NB. IL-10-Dependent and Independent Mechanisms Are Involved in the Cardiac Pathology Modulation Mediated by Fenofibrate in an Experimental Model of Chagas Heart Disease. Front Immunol. 2020 Sep 24;11:572178. doi:10.3390/ijms19061812

- Sbaraglini ML, Bellera CL, Quarroz Braghini J, Areco Y, Miranda C, Carrillo C, Kelly J, Buchholz B, Gelpi RJ, Talevi A, Alba Soto CD. Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease. Eur J Med Chem. 2019 Oct 10;184:111778. doi:10.1016/j.ejmech.2019.111778

- Llanos MA, Sbaraglini, ML, Villalba ML, Ruiz MD, Carrillo C, Alba Soto C, Talevi A, Angeli A, Parkkila S, Supuran CT and Gavernet L. 2020. A structure-based approach towards the identification of novel antichagasic compounds: Trypanosoma cruzi carbonic anhydrase inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 35:1, 21-30, doi:10.1080/14756366.2019.1677638

- Ágata C. Cevey , Federico N. Penas , Catalina D. Alba Soto, Gerardo A. Mirkin and Nora B. Goren. IL-10/STAT3/SOCS3 Axis Is Involved in the Anti-inflammatory Effect of Benznidazole. Front Immunol. 2019 Jun 4;10:1267. doi:10.3389/fimmu.2019.01267

- Pino-Martínez AM, Miranda CG, Batalla EI, González-Cappa SM, Alba Soto CD. IL-10 participates in the expansion and functional activation of CD8+ T cells during acute infection with Trypanosoma cruzi. J Leukoc Biol. 2019 Jan;105(1):163-175. doi:10.1002/JLB.3A0318-111RR

- Alba Soto C. Elimination of indigenous malaria in Argentina: history of a struggle and the risk of forgetting. Rev Argent Microbiol. 2019 Oct-Dec;51(4):289-291. doi: 10.1016/j.ram.2019.11.001

- Alberca LN, Sbaraglini ML, Morales JF, Dietrich R, Ruiz MD, Pino Martínez AM, Miranda CG, Fraccaroli L, Alba Soto CD, Carrillo C, Palestro PH, Talevi A. Cascade Ligand- and Structure-Based Virtual Screening to Identify New Trypanocidal Compounds Inhibiting Putrescine Uptake. Front Cell Infect Microbiol. 2018 May 25;8:173. doi:10.3389/fcimb.2018.00173

- Caeiro LD, Alba-Soto CD, Rizzi M, Solana ME, Rodriguez G, Chidichimo AM, Rodriguez ME, Sánchez DO, Levy GV, Tekiel V. The protein family TcTASV-C is a novel Trypanosoma cruzi virulence factor secreted in extracellular vesicles by trypomastigotes and highly expressed in bloodstream forms. PLoS Negl Trop Dis. 2018 May 4;12(5):e0006475. doi:10.1371/journal.pntd.0006475

- Repetto SA, Ruybal P, Batalla E, López C, Fridman V, Sierra M, Radisic M, Bravo PM, Risso MG, González Cappa SM, Alba Soto CD. Strongyloidiasis Outside Endemic Areas: Long-term Parasitological and Clinical Follow-up After Ivermectin Treatment. Clin Infect Dis. 2018 May 2;66(10):1558-1565. doi:10.1093/cid/cix1069

- Sbaraglini ML, Bellera CL, Fraccaroli L, Larocca L, Carrillo C, Talevi A, Alba Soto CD. Novel cruzipain inhibitors for the chemotherapy of chronic Chagas disease. Int J Antimicrob Agents. 2016 Jul;48(1):91-95. doi:10.1016/j.ijantimicag.2016.02.018

- Repetto SA, Ruybal P, Solana ME, López C, Berini CA, Alba Soto CD, Cappa SM. Comparison between PCR and larvae visualization methods for diagnosis of Strongyloides stercoralis out of endemic area: A proposed algorithm. Acta Trop. 2016 May;157:169-77. doi:10.1016/j.actatropica.2016.02.004

- Batalla EI, Pino Martínez AM, Poncini CV, Duffy T, Schijman AG, González Cappa SM, Alba Soto CD. Impairment in natural killer cells editing of immature dendritic cells by infection with a virulent Trypanosoma cruzi population. J Innate Immun. 2013;5(5):494-504. doi:10.1159/000350242

- Alba Soto CD, Solana ME, Poncini CV, Pino-Martinez AM, Tekiel V, González-Cappa SM. Dendritic cells devoid of IL-10 induce protective immunity against the protozoan parasite Trypanosoma cruzi. Vaccine. 2010 Oct 28;28(46):7407-13. doi:10.1016/j.vaccine.2010.08.105

- Poncini CV, Giménez G, Pontillo CA, Alba-Soto CD, de Isola EL, Piazzón I, Cappa SM. Central role of extracellular signal-regulated kinase and Toll-like receptor 4 in IL-10 production in regulatory dendritic cells induced by Trypanosoma cruzi. Mol Immunol. 2010 Jul;47(11-12):1981-8. doi:10.1016/j.molimm.2010.04.016